CTEC Global X CleanTech ETF

HAYWARD, Calif., Dec. 14 /PRNewswire-FirstCall/ -- Cholestech Corporation (NASDAQ:CTEC), a leading manufacturer of point of care testing devices, announced that is has joined forces with GE Healthcare, a unit of General Electric Company (NYSE:GE), to raise awareness on issues that affect women's health with the "GE Women's Health and Wellness Tour." The national, mobile tour designed to educate women about their own health and wellness was launched in October 2004 in conjunction with Breast Cancer Awareness Month. The GE Women's Health and Wellness Tour features a custom-designed, 53-foot vehicle that is fully equipped with the latest, state-of-the art clinical technology to offer education for women regarding breast cancer, cardiovascular disease, osteoporosis and other health issues. Attendees will have the opportunity to learn about how mammograms are performed and the benefits of digital mammography. In addition, the tour will provide blood pressure, cholesterol, pulse, and bone density screenings. As part of Cholestech's sponsorship, the cholesterol screening is being conducted using the Cholestech LDX(R) System, a leading cholesterol monitoring tool which generates comprehensive lab-accurate results in minutes. Using a simple finger-stick, the LDX System can measure cholesterol, glucose and liver enzymes, and now, high sensitivity C-Reactive Protein (hs-CRP). This enhances the ability to quickly identify patients with risk factors for heart disease, enabling physicians to focus on getting patients on the right treatment sooner and making sure they stay on the right therapeutic mix. "Cholestech is proud to support the GE Women's Health Tour and we commend GE Healthcare for their commitment to improving education about and access to the latest technologies for the detection, diagnosis and treatment of health issues that impact women the most," said Warren E. Pinckert II, president and CEO of Cholestech. "Clearly, GE had several options to choose from for cholesterol screening and we believe that the selection of the LDX System is another validation of our ability to offer the highest quality point of care diagnostic tools that can generate lab-accurate results in minutes." The Cholestech LDX System has been certified by the Cholesterol Reference Method Laboratory Network (CRMLN), which validates that the system meets the gold standard for accuracy and reproducibility developed by the Centers for Disease Control and Prevention (CDC) for the measurement of total cholesterol and HDL cholesterol consistent with National Cholesterol Education Program analytical goals. About GE Healthcare GE Healthcare provides transformational medical technologies that are shaping a new age of patient care. Our expertise in medical imaging and information technologies, medical diagnostics, patient monitoring systems, drug discovery, and biopharmaceutical manufacturing technologies is helping physicians around the world develop new ways to predict, diagnose, inform and treat disease, so their patients can live their lives to the fullest. GE Healthcare's broad range of products and services enable healthcare providers to better diagnose and treat cancer, heart disease, neurological diseases, and other conditions earlier. Our vision for the future is to enable a new "early health" model of care focused on earlier diagnosis, pre-symptomatic disease detection and disease prevention. Headquartered in the United Kingdom, GE Healthcare is a $15 billion unit of General Electric Company. Worldwide, GE Healthcare employs more than 43,000 people committed to serving healthcare professionals and their patients in more than 100 countries. For more information about GE Healthcare, visit our website at http://www.gehealthcare.com/. About Cholestech Cholestech is committed to enabling people to lead longer, healthier and more active lives. Cholestech provides easy to use, accessible diagnostic tools and information to health care practitioners in over 35 countries around the world. Cholestech offers efficient and economic diagnostic testing for cholesterol and related lipids, blood glucose and glycemic control, high sensitivity C-Reactive Protein and liver function at the point of care. Health care providers can use the CLIA-waived Cholestech LDX(R) and GDX(TM) Systems to initiate and monitor the progress of patient therapy. By providing effective disease management solutions, Cholestech's goal is to be a leading provider of diagnostic tools and information for immediate risk assessment and therapeutic monitoring of heart disease and diabetes. NOTE: Cholestech LDX(R) is a registered trademark and Cholestech GDX(TM) is a trademark of Cholestech Corporation. All other trademarks mentioned in this document are the property of their respective owners. For more information about Cholestech and its products visit us on the web at http://www.cholestech.com/. DATASOURCE: Cholestech Corporation CONTACT: media, Chris K. Joseph of ckj Communications, +1-510-339-2293, or , for Cholestech; or Banks Willis of GE Healthcare, +1-262-337-3050, or Web site: http://www.gehealthcare.com/ Web site: http://www.cholestech.com/

Copyright